arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

IMMUCELL CORP /DE/

ICCC
$9.94 ▼ -0.37 (-3.54%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
41
Health
Weak
Bearish
auto_awesome

Analytical Summary

IMMUCELL CORP /DE/ faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $89.7M
Dividend Yield —
Revenue Growth 4.3% ↘
Op. Margin 6.0% ↗
ROIC 4.6% ↗
FCF / Share $0.14 ↗
Trailing P/E —
Price / Book 3.3x
FCF Yield 1.4%
Debt / Equity 0.34
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$27.64M
↑ +4.3% —
Net Income Profit after all expenses
$-1.04M
↑ +51.8% —
Operating Margin Operating profit as % of sales
6.0%
↑ +196.4% 46th
FCF / Share Free cash flow per share
$0.14
↑ +1127.9% —
Long-Term Debt Long-term obligations
$9.10M
↑ +0.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability →
37
Returns ↓
39
Financial Health ↑
65
Cash Quality
9

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters